EUVIMEDEUVIMED entdecken
Fallbericht

Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?

T Cooksley, J Weaver, M McNamara, P Lorigan

QJM: An International Journal of Medicine · 04.06.2024 · 117 (5) · 373-374

DOI: 10.1093/qjmed/hcae006 ↗

Kurz gefasst

Fallbericht in der Zeitschrift QJM: An International Journal of Medicine, online erschienen am 16.01.2024. Verfasst von T Cooksley und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Christie NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myasthenia Gravis, Myocarditis, Myositis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis occur early after initiation of therapy and are associated with significant mortality. The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis tends to be more aggressive than its de novo counterparts and management strategies must be adapted to recognize this. A window of opportunity may exist in the early stages of treatment with immune checkpoint inhibition to facilitate earlier recognition and treatment of this rare and aggressive toxicity. Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis occur early after initiation of therapy and are associated with significant mortality.1,2 The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis tends to be more aggressive than its de novo counterparts and management strategies must be adapted to recognize this. We describe a presentation of this condition, which may offer further insights into its disease course and management. A 66-year-old lady with metastatic distal bile duct cholangiocarcinoma presented 7 days following the first dose of Pembrolizumab with nausea and fatigue. She did not describe chest pain, dyspnoea, muscle pains or ocular symptoms. She had no infective symptoms. She had no other significant medical history. She had never smoked. On examination, she had bilateral ptosis. She had no other significant neurological findings. Her blood pressure was 140/70 mmHg with a pulse rate of 70 bpm. Her cardiovascular and respiratory examinations were unremarkable. An electrocardiogram (ECG) performed due to her ptosis showed sinus rhythm with diffuse ST changes. Her Troponin was elevated at 5298 ng/l (see Figure 1) with a Creatinine Kinase (CK) measuring 470 iU/l. Her other blood tests were unremarkable. Trend of Troponin I (solid line) levels and ACh-R antibody (dashed line) titres during course of immune-mediated myasthenia gravis, myocarditis and myositis. She commenced on intravenous methylprednisolone at a dose of 1 mg/kg and continuous cardiac monitoring was commenced. Pyridostigmine was not started on the basis that she only had ptosis. An autoantibody screen, including glutamic acid decarboxylase (GAD), muscle specific kinase (MuSK) and acetylcholine receptor (ACh-R), was sent. Her symptoms remained static over the next 24 h with no progression of her ocular myasthenic symptoms, no arrhythmias on her cardiac monitoring and no dynamic changes on her ECG. However, there was a marked rise in her Troponin to 14 782 ng/l. She thus commenced 1 g/kg of intravenous immunoglobulin. Over the next week, she made steady progress. Her bilateral ptosis resolved. Her CK and Troponin decreased. An echocardiogram conducted on Day 2 demonstrated severe left ventricular systolic dysfunction with widespread regional wall motion abnormalities, which were confirmed on subsequent cardiac magnetic resonance imaging. Her Ach-R was borderline at 0.39 nmol/l, with a grossly elevated GAD antibody (155 µ/ml). Her steroids were converted to an oral weaning course and she was commenced on mycophenolate mofetil 1 g BD. She was discharged on Day 7 with a plan for weekly clinical reviews. One week later, she remained fatigued but with no other new symptoms and no recurrence of her ptosis. A repeat ACh-R was positive with a titre 0.62 nmol/l. She noted recurrence of her bilateral ptosis 12 days following her initial discharge. She was treated with a further 3 days of IV methylprednisolone and Abatacept (750 mg). She was commenced on Pyridostigmine 60 mg TDS. She made a full recovery with complete resolution of her ptosis and no progression to new myasthenic symptoms. One week later, her ACh-R was undetectable. She continued on a weaning course of steroids, mycophenolate mofetil and pyridostigmine. Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis is associated with significant mortality. Some cases have been suggestive that the triad may not occur at the same time but has a rapidly sequential trajectory with an initial myocarditis followed by a fulminant aggressive myasthenia gravis. Recognition of this progression is essential as early initiation of corticosteroid therapy and adjunct immunosuppressive therapy with intravenous immunoglobulins or plasma exchange improves outcomes.1,3,4 This case adds to the evidence that aggressive early treatment may prevent the progression and improve outcome in immune checkpoint inhibitor-related myasthenia gravis, myocarditis and myositis. Further, there are two important insights from this case; firstly that the triad may initially start with a relatively asymptomatic myocarditis and secondly that treatment at this stage may be able to stem the development of a fulminant myasthenic presentation. These findings suggest a window of opportunity may exist in the early stages of treatment with immune checkpoint inhibition to facilitate earlier recognition and treatment of this rare and aggressive toxicity. Prospective studies of cardiac biomarker monitoring may be warranted. Tim Cooksley (Writing—original draft [equal]), Jamie Weaver (Writing—review & editing [equal]), Mairead McNamara (Writing—review & editing [equal]), and Paul Lorigan (Writing—review & editing [equal]) None of the authors have a conflict of interest relating to this case report.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMyasthenia GravisMyocarditisMyositisFemaleHumansAged

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • The Christie NHS Foundation Trust, Manchester, UK.
  • University of Manchester, Manchester, UK.

Zitieren

APA

Cooksley, T., Weaver, J., McNamara, M., & Lorigan, P. (2024). Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?. QJM: An International Journal of Medicine, 117(5), 373-374. https://doi.org/10.1093/qjmed/hcae006

Vancouver

Cooksley T, Weaver J, McNamara M, Lorigan P. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?. QJM: An International Journal of Medicine. 2024;117(5):373-374. doi:10.1093/qjmed/hcae006

BibTeX
@article{Cooksley2024,
  author = {Cooksley, T and Weaver, J and McNamara, M and Lorigan, P},
  title = {Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?},
  journal = {QJM: An International Journal of Medicine},
  year = {2024},
  volume = {117},
  number = {5},
  pages = {373--374},
  doi = {10.1093/qjmed/hcae006}
}
Kostenlos starten →